The International Journal of Biochemistry & Cell Biology
Medicine in focusAcute myeloid leukemia: Therapeutic impact of epigenetic drugs
Introduction
Leukemia is the manifestation of the inappropriate expansion of hematopoietic progenitor cells, often due to a block of cell maturation at early stages in the cell lineages that give rise to the various cell types that constitute normal blood. Through recurrent specific genetic aberrations, such as chromosome breaks, rearrangements that transfer genes into distinct genetic contexts or generate fusion proteins with altered functionalities, genes have been identified whose altered functionality was critically or causally linked to leukemogenesis. In particular, acute myeloid leukemia (AML) is a malignant tumour of hematopoietic precursor cells of non-lymphoid lineage, with an annual incidence of 1/10,000 and a frequency that increases with age (Table 1). While AMLs were previously sub-divided following the French–American–British (FAB) classification according to blast morphology, immunophenotype, cytogenetics and clinical features, the WHO classification incorporates in addition to those parameters more recent discoveries regarding the genetics and clinical features of AML in an attempt to define entities that are biologically homogeneous and that have prognostic and therapeutic relevance (WHO; Table 2). The most studied AML subtype is acute promyelocytic leukemia (APL; FAB M3) of which more than 90% display the chromosomal translocation t(15;17) that generates the PML–RARα fusion protein comprising parts of the PML and retinoic acid receptor alpha (RARα) genes. In the past years, the functions that have been altered by the presence of different oncogenic fusion proteins such as PML–RARα in APL or AML–ETO in some AML are increasingly well understood. However, only recently, we have begun to unravel the epigenetic (and thus in principle, reversible) phenomena that contribute, together with genetic aberrations, to the development of leukemia, and malignancies in general, by the recognition and dissection of multi-subunit chromatin-modifying machineries. Epigenetic phenomena refer to ‘mitotically and meiotically heritable changes in gene expression that are not coded in the DNA sequence itself’ (Egger, Liang, Aparicio, & Jones, 2004). But often the term ‘epigenetic’ is in general applied to describe events originated from the post-translational modification of the main chromatin components, histones and DNA, or even transcription factors. Moreover, an ‘histone code’ hypothesis has been formulated (Strahl & Allis, 2000) to propose that the panel of modifications such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation or ADP ribosylation deposit epigenetically relevant information at defined genetic loci to regulate most, if not all, chromatin-templated processes (see Fig. 1 for epigenetic modifications of the histone tails). Theoretically, the complexity of such a ‘histone code’ would by far exceed that of the classical genetic code. However, an alternative view is that histone modifications may just correspond to steps in a complex signalling process (Kurdistani, Tavazoie, & Grunstein, 2004). Importantly, modifications of the DNA and histone modification patterns have both been associated with cancer and epigenetic deregulations are increasingly recognized as mechanisms exploited by tumors to silence gene programs that regulate growth, DNA repair and apoptosis (Ayton, Chen, & Cleary, 2004; Egger et al., 2004, Esteller, 2005; Feinberg & Tycko, 2004; Laird, 2003, Villa et al., 2004). Notably, in contrast to genetic modifications, epigenetic alterations are transient and can be reversed, at least partially, by treatment with epigenetic drugs (Brueckner & Lyko, 2004; Somech, Izraeli, & Simon, 2004). Pioneering work has unraveled the link between oncogenic fusion proteins (such as PML–RARα, PLZF–RARα, AML–ETO, etc.) – that cause acute myeloid leukaemia – with the aberrant recruitment of histone deacetylases and DNA methyltransferase, enzymes involved in gene silencing. Various types of inhibitors (HDAC-Is and DNMT-Is) have been generated and we are now witnessing the elucidation of structure–activity relationships of HDAC-Is (Marks, Richon, Miller, & Kelly, 2004) and the mechanism(s) of their anti-cancer action (Insinga et al., 2005, Nebbioso et al., 2005). Moreover, therapies are being explored in which two epigenetic (e.g. an HDAC and a DNA methyltransferase inhibitor) drugs or an epigenetic and a signalling drug (e.g. HDAC-I and retinoic acid) are combined to specify action, decrease effective concentration due to drug synergy and thus, reduce side effects.
Section snippets
Genetic aberrations causing acute myeloid leukemia affect epigenetic gene regulation
Acute myeloid leukemia (AML), the collective description of a variety of myeloid leukemias characterized by a block of differentiation at various early stages in the myeloid lineage, is frequently associated with the common karyotype abnormalities that affect a number of specific genes believed to regulate critical steps in normal myelopoiesis. Common abnormalities cluster often, but not always, with common AML subtypes. In some cases, such as the t(15;17) translocation generating the PML–RARα
Differentiation therapy of myeloid leukaemia
Cancer ‘differentiation therapy’ refers to a novel type of treatment by which a (signaling, epigenetic) drug forces a tumor cell to adapt a more, preferentially terminally, differentiated state that leads to apoptosis. Such drugs do not necessarily display the toxicity commonly associated with chemotherapy. Presently, several compounds are in clinical use but the most successful example of differentiation therapy is APL with the use of all-trans retinoic acid which combined with chemotherapy
Coming of age: Epigenetic therapy of leukemia
Solid evidence demonstrates that in addition to genetic alteration, aberrant epigenetic regulation, such as silencing of tumor suppressors, is used by cancer cells to escape growth and death control mechanisms (for review and references see Esteller, 2005). Thus, compounds able to influence the epigenetic status of a cell have promise for cancer treatment. DNMT-Is have been already largely tested in cancers. One of the most recent results obtained 30–60% response rates in leukemias (Issa et
Conclusions and perspectives
The progresses on the functional characterization of DNMTs and HDACs will enable a more rational approach to drug design. Targeted design of epigenetic modulators together with the development of molecular models for screening purposes will facilitate the identification of more specific and selective molecules. Furthermore, defining the action spectra of HDACs, using genetics, antisense oligonucleotides, siRNAs and inhibitors, will provide the basis for targeted clinical use of potentially very
Acknowledgements
Supported by the European Community (QLG1-CT-2000-01935 and QLK3-CT-2002-02029), the Institut Nationale de la Santè et de la Recherche Médicale, the Centre National de La Recherche Scientifique, the Hòpital Universitaire de Strasbourg, the Association for International Cancer Research, the Association pour la Recherche sur le Cancer, the Fondation de France, the Regione Campania Legge 5/2002, PRIN 2004-055579, the Ministero dell Salute R.F.02/184, the French-Italian GALILEO project.
References (53)
- et al.
Retinoids and TRAIL: Two cooperating actors to fight against cancer
Vitam. Horm.
(2004) - et al.
DNA methyltransferase inhibitors: Old and new drugs for an epigenetic cancer therapy
Trends Pharmacol. Sci.
(2004) - et al.
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP
Cancer Cell
(2003) Molecular genetics of human leukemias: New insights into therapy
Semin. Hematol.
(2002)- et al.
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Cancer Cell
(2004) - et al.
Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23; q13)
Blood
(1997) - et al.
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
Blood
(2004) - et al.
Mapping global histone acetylation patterns to gene expression
Cell
(2004) - et al.
Histone deacetylase inhibitors
Adv. Cancer Res.
(2004) - et al.
MLL targets SET domain methyltransferase activity to Hox gene promoters
Mol. Cell
(2002)
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation
Mol. Cell
Reciprocal products of chromosomal translocations in human cancer pathogenesis: Key players or innocent bystanders?
Trends Mol. Med.
The role of PML in tumor suppression
Cell
Histone deacetylase inhibitors—A new tool to treat cancer
Cancer Treat Rev.
Epigenetic gene silencing in acute promyelocytic leukemia
Biochem. Pharmacol.
A sumoylation site in PML/RARA is essential for leukemic transformation
Cancer Cell
Common themes in the pathogenesis of acute myeloid leukemia
Oncogene
The promise of retinoids to fight against cancer
Nat. Rev. Cancer
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
Nat. Med.
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
Mol. Cell Biol.
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein
Mol. Cell Biol.
RAR-independent RXR signaling induces t(15;17) leukemia cell maturation
EMBO J.
The translocation t(8;16)(p11; p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein
Nat. Genet.
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22)
Genes Chromosomes Cancer
Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
EMBO J.
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
Science
Cited by (44)
The natural phenolic peperobtusin A induces apoptosis of lymphoma U937 cells via the Caspase dependent and p38 MAPK signaling pathways
2018, Biomedicine and PharmacotherapyCitation Excerpt :Acute myeloid leukemia (AML) was a malignant tumor of hematopoietic precursor cells of myeloid lineage [1], characterized by infiltration of the blood and bone marrow, and other tissues by abnormally differentiated, and occasionally poorly differentiated cells of the hematopoietic system.
Valproic acid downregulates heme oxygenase-1 independently of Nrf2 by increasing ubiquitination and proteasomal degradation
2017, Biochemical and Biophysical Research CommunicationsCitation Excerpt :This results in increased expression of many genes and seems to be an upstream effector of other altered pathways upon VA treatment [19]. Importantly, it was shown to be a promising compound against various cancers, as it enhanced differentiation, inhibited proliferation and increased apoptosis of cancer cells [20–22]. However, mechanisms governing the VA-mediated action is not fully understood.
Ethyl acetate extract of Peperomia tetraphylla induces cytotoxicity, cell cycle arrest, and apoptosis in lymphoma U937 cells
2016, Biomedicine and PharmacotherapyCitation Excerpt :Leukemia is the leading cause of cancer death among men for those aged 20–39 years in USA, 2011 [3]. Acute myeloid leukemia (AML) is a type of leukemia, and is the malignant tumor of hematopoietic precursor cells of myeloid lineage [4], characterized by the rapid growth of immature leukemia cells and a decrease in the number of mature normal blood cells. Leukemia accounts for almost one-third of all cancers (including benign brain tumors) diagnosed in children aged 0–14 years.
HDAC modulation and cell death in the clinic
2012, Experimental Cell ResearchCitation Excerpt :These “readers” are a family of evolutionarily conserved protein-interaction modules, characterized by a four-helix bundle structure [1]. HATs and HDACs can be altered both for expression and function, establishing a dramatic pathological phenotype causing or contributing to diseases such as cancer, auto-immune disorders and neurological pathologies [2–4]. Thus, HDACs represent promising therapeutic targets given that HDACis might reverse aberrant epigenetic states associated with cancer [5,6].
Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead
2009, International Journal of Biochemistry and Cell BiologyNew pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations
2009, International Journal of Biochemistry and Cell Biology